Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Apply
Mavrostobart & PD-1 Inhibitor
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step